Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma
Year: 2026
Type: article
Abstract: BACKGROUND The proportion of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is as high as 85.69% among HCC patients in China. Current anti-HBV drugs include nucleos(t)ide analogs (NAs) and interferon (IFN). AIM To compare the impact of NAs and IFN therapy on the occurrence of HCC in patients at high risk of HBV-related HCC. METHODS We enrolled 368 patients with high risk of HBV-related HCC, and 120 received subcutaneous injections of IFN, with or without NAs, constituting the IFN group. The remaining 248 patients were assigned to the NAs group, and received treatment with NAs alone. RESULTS For patients with a high risk of HBV-related HCC, after a 5-year treatment period, HCC incidence in the IFN group was 2.54%, while the NAs group showed a significantly higher incidence of 25.74% (P < 0.001). After propensity score matching, HCC incidence in the IFN and NAs groups was 2.94% and 22.0%, respectively (P < 0.001). CONCLUSION IFN-based therapy, compared with NAs, significantly reduced the risk of HCC in patients with high risk of HBV-related HCC.
DOI: 10.4251/wjgo.123962
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7204883362
